Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells

被引:30
作者
Bolovan-Fritts, CA
Trout, RN
Spector, SA
机构
[1] Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Ctr AIDS Res, La Jolla, CA 92093 USA
关键词
D O I
10.1128/JVI.78.23.13173-13181.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cytomegalovirus (CMV) infection has been linked to inflammation-related disease processes in the human host, including vascular diseases and chronic transplant rejection. The mechanisms through which CMV affects the pathogenesis of these diseases are for the most part unknown. To study the contributing role of the host immune response to CMV in these chronic inflammatory processes, we examined endothelial cell interactions with peripheral blood mononuclear cells (PBMC). Endothelial cultures were monitored for levels of fractalkine induction as a marker for initiating the host inflammatory response. Our results demonstrate that in the presence of CMV antigen PBMC from normal healthy CMV-seropositive donors produce soluble factors that induce fractalkine in endothelial cells. This was not observed in parallel assays with PBMC from seronegative donors. Examination of subset populations within the PBMC further revealed that CMV antigen-stimulated CD4(+) T cells were the source of the factors, gamma interferon and tumor necrosis factor alpha, driving fractalkine induction. Direct contact between CD4(+) cells and the endothelial monolayers is required for this fractalkine induction, where the endothelial cells appear to provide antigen presentation functions. These findings indicate that CMV may represent one member of a class of persistent pathogens where the antigen-specific T-cell response can result in the induction of fractalkine, leading to chronic inflammation and endothelial cell injury.
引用
收藏
页码:13173 / 13181
页数:9
相关论文
共 43 条
  • [1] Fractalkine preferentially mediates arrest and migration of CD16+ monocytes
    Ancuta, P
    Rao, R
    Moses, A
    Mehle, A
    Shaw, SK
    Luscinskas, FW
    Gabuzda, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (12) : 1701 - 1707
  • [2] Bettinotti Maria P., 2003, Human Immunology, V64, pS73, DOI 10.1016/j.humimm.2003.08.132
  • [3] Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus
    Bitmansour, AD
    Waldrop, SL
    Pitcher, CJ
    Khatamzas, E
    Kern, F
    Maino, VC
    Picker, LJ
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (03) : 1151 - 1163
  • [4] BRUNETTI P, 1994, DIABETES NUTR METAB, V7, P1
  • [5] Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2
    Compton, T
    Kurt-Jones, EA
    Boehme, KW
    Belko, J
    Latz, E
    Golenbock, DT
    Finberg, RW
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (08) : 4588 - 4596
  • [6] Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 -: Rapid communication
    Feng, LL
    Chen, SZ
    Garcia, GE
    Xia, YY
    Siani, MA
    Botti, P
    Wilson, CB
    Harrison, JK
    Bacon, KB
    [J]. KIDNEY INTERNATIONAL, 1999, 56 (02) : 612 - 620
  • [7] Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses
    Fraticelli, P
    Sironi, M
    Bianchi, G
    D'Ambrosio, D
    Albanesi, C
    Stoppacciaro, A
    Chieppa, M
    Allavena, P
    Ruco, L
    Girolomoni, G
    Sinigaglia, F
    Vecchi, A
    Mantovani, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) : 1173 - 1181
  • [8] Garton KJ, 2001, J BIOL CHEM, V276, P37993
  • [9] Control of MHC class I traffic from the endoplasmic reticulum by cellular chaperones and viral anti-chaperones
    Gruhler, A
    Früh, K
    [J]. TRAFFIC, 2000, 1 (04) : 306 - 311
  • [10] Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection
    Haskell, CA
    Hancock, WW
    Salant, DJ
    Gao, W
    Csizmadia, V
    Peters, W
    Faia, K
    Fituri, O
    Rottman, JB
    Charo, IF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (05) : 679 - 688